Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Teleflex ( (TFX) ) has shared an announcement.
Teleflex reported its financial results for the second quarter ending June 29, 2025, with a GAAP revenue increase of 4.2% compared to the previous year. The company’s adjusted diluted EPS also rose to $3.73 from $3.42. Teleflex raised its full-year 2025 revenue and EPS guidance, reflecting the impact of its recent acquisition of BIOTRONIK’s Vascular Intervention business. This acquisition is expected to strengthen Teleflex’s global footprint in the peripheral intervention market, complementing its existing portfolio and supporting its value creation strategy.
The most recent analyst rating on (TFX) stock is a Buy with a $285.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Spark’s Take on TFX Stock
According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.
Teleflex’s overall stock score reflects solid financial health and efficient cash management as its key strengths. However, technical indicators and valuation suggest caution, while the latest earnings call presents a mixed outlook with significant challenges in revenue and margin pressures, particularly due to tariffs and declining performance in key segments.
To see Spark’s full report on TFX stock, click here.
More about Teleflex
Teleflex Incorporated operates in the medical technology industry, focusing on providing products and services in areas such as vascular access, interventional, anesthesia, surgical, and interventional urology. The company has a significant market presence in the cath lab and peripheral intervention market, enhanced by its acquisition of BIOTRONIK’s Vascular Intervention business.
Average Trading Volume: 533,551
Technical Sentiment Signal: Sell
Current Market Cap: $5.1B
Learn more about TFX stock on TipRanks’ Stock Analysis page.